News - Seismic Therapeutic | Seismic Therapeutic

November 18, 2024

Seismic Therapeutic Presents New Preclinical Data for S-4321, a Next Generation PD 1:FcγRIIb-Selective Bifunctional Agonist Antibody for the Treatment of Autoimmune Disease, at ACR Convergence 2024

POSTER:
S-4321, a novel dual-cell bidirectional PD-1:FcgRIIb selective agonist antibody for the treatment of autoimmune disease

POSTER:
Preclinical pharmacology of S-1117, a novel engineered Fc-fused IgG degrading enzyme, for chronic treatment of autoantibody-mediated diseases

November 7, 2024

Seismic Therapeutic to Participate in Upcoming Investor Conferences

November 6, 2024

Seismic Therapeutic Presents Data Demonstrating Key Capabilities and Broad Utility of Its Machine Learning-enabled IMPACT Platform to Create Novel Biologic Medicines

November 5, 2024

Seismic Therapeutic Announces Presentations at Upcoming Scientific and Medical Conferences

October 15, 2024

Seismic Therapeutic Presents New Preclinical Data on S-1117 in Autoantibody-Mediated Diseases Including Myasthenia Gravis at MGFA Scientific Session at AANEM Annual Meeting

POSTER:
Preclinical pharmacology of S-1117, a novel engineered Fc-fused IgG cleaving enzyme, for chronic treatment of autoantibody-mediated diseases including myasthenia gravis

September 30, 2024

Seismic Therapeutic Announces Participation at Upcoming October Scientific and Medical Conferences

September 23, 2024

Seismic Therapeutic Appoints Julie Eastland as Independent Board Director

August 26, 2024

Seismic Therapeutic to Participate in Upcoming Investor Conferences

June 25, 2024

Seismic Therapeutic Appoints Brendan St. Amant as General Counsel

June 4, 2024

Seismic Therapeutic Announces Participation at Multiple Upcoming Scientific Conferences in June 2024

May 29, 2024

Seismic Therapeutic to Participate in Upcoming June Investor Conferences

April 12, 2024

Seismic Therapeutic Presents Preclinical Data on S-1117, its Novel Pan-IgG Protease Addressing Multiple Pathogenic Mechanisms in Autoimmune Disease, at American Academy of Neurology (AAN) 2024

POSTER:
Preclinical pharmacology of S-1117, a novel engineered Fc-fused IgG cleaving enzyme, for chronic treatment of autoantibody-mediated diseases

April 9, 2024

Seismic Therapeutic Announces Participation at Multiple Upcoming Scientific Conferences in April and May 2024

March 8, 2024

Seismic Therapeutic to Present Preclinical Data for Novel Immunoglobulin Sculpting Enzyme at AAN Annual Meeting

December 4, 2023

Seismic Therapeutic Closes $121 Million Series B Financing to Advance Immunology Pipeline Optimized by its Machine Learning Platform

October 11, 2023

Seismic Therapeutic to Participate in Upcoming Scientific Meetings

September 21, 2023

Seismic Therapeutic Selected as an Endpoints 11 Most Promising Biotech Startup

June 14, 2023

Seismic Therapeutic Announces Presentation of Preclinical Data for Advancing Novel Biologics Drug Programs at the 23rd Annual Meeting of the Federation of Clinical Immunology Societies

May 11, 2023

Seismic Therapeutic Announces Presentation of Preclinical Data Demonstrating Advances in Novel Biologics Discovery at the PEGS Boston Summit

May 9, 2023

Seismic Therapeutic Announces Presentation of Preclinical Data for Immunoglobin Sculpting Enzyme and Dual-Cell Bidirectional Antibody Programs at IMMUNOLOGY 2023

April 11, 2023

Founder Q&A with Jeff Ravetch, MD, PhD

March 27, 2023

Seismic Therapeutic Appoints Melanie Manning as Chief People Officer

January 4, 2023

Seismic Therapeutic Selected for BioSpace’s NextGen Class of 2023

December 9, 2022

Seismic Therapeutic Named Emerging Company of the Year in Life Sciences at 2022 NEVY Awards

November 8, 2022

Founder Q&A with Tim Springer, PhD

September 28, 2022

Seismic Therapeutic Congratulates Dr. Timothy A. Springer, Winner of the 2022 Lasker Award

May 3, 2022

Seismic Therapeutic Appoints Maude Tessier, PhD, as Chief Business Officer

April 13, 2022

Seismic Therapeutic Appoints Eric Larson as Senior Vice President of Finance and Heather Vital as Vice President of R&D Strategy

February 9, 2022

Seismic Therapeutic Launches with $101 Million Series A Financing to Usher in a New Era of Immunology Drug Development Integrating Machine Learning

More

Our Awards

Most Promising Biotech Startup 2023
Endpoints 11

NextGen Class of 2023
Biospace

Extraordinary Women Advancing Healthcare in Massachusetts 2022
The Women's Edge

NEVY Awards Emerging Company of the Year in Life Sciences 2022
New England Venture Capital Association

BostInno Fire Award
Boston Business Journal

Biotech Startup 2022 bioDiversity Award
LabCentral Ignite

Women Who Lead in Life Sciences 2022
Boston Business Journal

This links to an external website.